Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ludovic Ferrer

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Advances in Radiation Oncology|January 16, 2026
Dosimetric Feasibility of Dose-Painting Radiation Therapy for Targeting Hypoxia in Prostate Cancer on a Novel Ring Gantry Radiation Therapy SystemTanguy Perennec, Karine A Al Feghali, Dorine de Jong, et al.
Oncotarget|March 9, 2018
Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using <sup>18</sup>F-fluoromisonidazole PET/CT: a pilot studyStéphane Supiot, Caroline Rousseau, Mélanie Dore, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Reoxygenation during radiotherapy in intermediate-risk prostate cancerStéphane Supiot, Caroline Rousseau, Mélanie Dore, et al.
The Prostate|December 15, 2018
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changesMatthieu Barbaud, Mathieu Frindel, Ludovic Ferrer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2006
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trialFrançoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, et al.
Seminars in Oncology|December 3, 2014
Radioimmunoconjugates for the treatment of cancerFrançoise Kraeber-Bodéré, Caroline Bodet-Milin, Caroline Rousseau, et al.
The Prostate|August 18, 2019
Preliminary results of a <sup>68</sup> Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-makingCaroline Rousseau, Maelle Le Thiec, Ludovic Ferrer, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 6, 2012
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patientsCaroline Rousseau, Ludovic Ferrer, Stéphane Supiot, et al.
Cancers|June 13, 2020
Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal CancerMaelle Le Thiec, Aude Testard, Ludovic Ferrer, et al.
Frontiers in Medicine|December 8, 2015
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsCaroline Bodet-Milin, Ludovic Ferrer, Aurore Rauscher, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Advances in Radiation Oncology|January 16, 2026
Dosimetric Feasibility of Dose-Painting Radiation Therapy for Targeting Hypoxia in Prostate Cancer on a Novel Ring Gantry Radiation Therapy SystemTanguy Perennec, Karine A Al Feghali, Dorine de Jong, et al.
Oncotarget|March 9, 2018
Evaluation of tumor hypoxia prior to radiotherapy in intermediate-risk prostate cancer using <sup>18</sup>F-fluoromisonidazole PET/CT: a pilot studyStéphane Supiot, Caroline Rousseau, Mélanie Dore, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 3, 2019
Reoxygenation during radiotherapy in intermediate-risk prostate cancerStéphane Supiot, Caroline Rousseau, Mélanie Dore, et al.
The Prostate|December 15, 2018
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changesMatthieu Barbaud, Mathieu Frindel, Ludovic Ferrer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 4, 2006
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trialFrançoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, et al.
Seminars in Oncology|December 3, 2014
Radioimmunoconjugates for the treatment of cancerFrançoise Kraeber-Bodéré, Caroline Bodet-Milin, Caroline Rousseau, et al.
The Prostate|August 18, 2019
Preliminary results of a <sup>68</sup> Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-makingCaroline Rousseau, Maelle Le Thiec, Ludovic Ferrer, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 6, 2012
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patientsCaroline Rousseau, Ludovic Ferrer, Stéphane Supiot, et al.
Cancers|June 13, 2020
Prognostic Impact of Pretherapeutic FDG-PET in Localized Anal CancerMaelle Le Thiec, Aude Testard, Ludovic Ferrer, et al.
Frontiers in Medicine|December 8, 2015
Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer PatientsCaroline Bodet-Milin, Ludovic Ferrer, Aurore Rauscher, et al.
Pageof 6